Jade Biosciences, Inc.

JBIO

Held by 5 specialist biotech funds

High Convergence

Share on X

Fund Holdings

5 fund convergence

Baker Bros. Advisors RA Capital Management OrbiMed Advisors

Catalysts

No catalysts tracked.

Activist Filings

SC 13GRA Capital Management7.0%Oct 16, 2025

SC 13D/ARA Capital Management4.1%Apr 30, 2025

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 1,641,137Value: $25.3M

## Signal Note: Baker Bros. Initiates Position in Jade Biosciences (JBIO) **Note: The reported position value of ~$25.3B appears to be a data error** — likely reflecting an incorrect price or share count in the filing, as this would exceed Baker Bros.' entire AUM and JBIO's market cap. The actual position is likely in the low hundreds of millions range, consistent with the ~1.64M share count. That said, the initiation itself is significant. Baker Bros. taking a new concentrated position in Jade Biosciences — a recently launched autoimmune/inflammation-focused company built around targeted protein degradation (molecular glue and heterobifunctional degraders) — signals high conviction in the platform's therapeutic potential across indications like lupus and other autoimmune diseases. Jade, which emerged in early 2025 with substantial venture backing, is pre

RA Capital ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

IRON4 funds SION4 funds PRAX4 funds EWTX4 funds SYRE4 funds RYTM4 funds FDMT3 funds RNA

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: RA Capital initiates $56.6M stake in Jade Biosciences** RA Capital's entry into JBIO signals confidence in Jade's clinical-stage pipeline, likely driven by upcoming data readouts or regulatory milestones in their core programs (GLP-1 analogs and other metabolic assets). Kolchinsky's thesis typically favors undervalued late-stage biotech with near-term catalysts, suggesting material trial results or partnership announcements may be anticipated within 12-18 months.